Dr. Haluska has served as CEO of Anchiano (formerly BioCanCell) since October 2016. He served as Chief Medical Officer and Senior Vice President of Clinical R&D at ARIAD Pharmaceuticals, Inc., where he held overall responsibility for clinical development strategy. At ARIAD he led the clinical development and approval of ponatinib (marketed as Iclusig) in the US, EU and other territories, as well as the development of brigatinib (marketed as Alunbrig) approved in the US by the FDA.
Dr. Haluska graduated from Harvard College and the University of Pennsylvania School of Medicine, undertook medical training at Massachusetts General Hospital (MGH) and the Dana-Farber Cancer Institute (DFCI), and a fellowship at the Massachusetts Institute of Technology Center for Cancer Research. He became assistant professor of medicine at Harvard Medical School, and leader of the melanoma research programs at the MGH Cancer Center and the DFCI through the Dana-Farber Harvard Cancer Center. Subsequently he was deputy director of the Tufts New England Medical Center Cancer Center. He currently serves on the Board of Directors at Elicio Pharmaceuticals.
Mr. Burgin has served as Anchiano’s (formerly BioCanCell) CFO and COO since October 2016, having previously served as CEO from 2012 to 2016, and as CFO from 2011 to 2012. From 2006 to 2011, he was CFO of Radcom, Ltd. (NASDAQ: RDCM), a service assurance provider, and CFO of XTL Biopharmaceuticals (TASE: XTL, NASDAQ: XTLB), a drug development company, from 1999 to 2006, where he took an active role in the process of listing its shares on the NASDAQ, London Stock Exchange and TASE, and in raising $113 million in four financing rounds. Between 1997 and 1999, he was CFO of YLR Capital Markets, a publicly-traded Israeli investment bank, and rose to become a Senior Manager at Kesselman & Kesselman, the Israeli member of PricewaterhouseCoopers International, Ltd, between 1984 and 1997. He currently serves on the board of directors of Cellect Biotechnology Ltd. (NASDAQ:APOP). Mr. Burgin earned an M.B.A. and a B.A. in Accounting and Economics from Tel-Aviv University and is certified in Israel as a CPA.
Dr. David Kerstein has served as Anchiano’s Chief Medical Officer since November 2018. Prior to joining Anchiano, Dr. Kerstein served as Senior Medical Director of Oncology Clinical Research at Takeda Pharmaceuticals International Co., a global research and development-driven pharmaceutical company. At Takeda, he was the lung cancer clinical portfolio strategy lead and global clinical lead for the ALK inhibitor, brigatinib. Prior to that, Dr. Kerstein was Medical Director and then Senior Medical Director of Clinical Research at ARIAD Pharmaceuticals, Inc., where he was the medical lead for the brigatinib clinical development program, and led the initial New Drug Application and Marketing Authorization Application submissions and approvals for brigatinib. Previously, at Boston Biomedical, Dainippon Sumitomo Pharma Global Oncology, he was Director of Clinical Development and Regulatory Affairs. Dr. Kerstein received his M.D. from Tufts University School of Medicine and his B.S. in biology, summa cum laude, from Tufts University.
Dr. Knickerbocker is Senior Vice President, Clinical Development at Anchiano (formerly BioCanCell) since March 2018. Prior to this Dr. Knickerbocker led the Biomedical Data Sciences and Information group at ARIAD Pharmaceuticals from 2012 until its acquisition by Takeda in 2017. At ARIAD, he led statistics and data management functions through multiple successful oncology submissions. Prior to this, Dr. Knickerbocker served as a Vice President at Genzyme corporation from 2004 to 2012, where his positions included leading the biostatistics, data management, and medical writing functions for the transplant/oncology business and global head of biostatistics and statistical programming. From 1999 to 2004 Dr. Knickerbocker was the statistical site head for Pfizer Inc. in Ann Arbor, MI. From 1993 to 1999, he held positions at Eli Lilly and Company, leading projects in women’s health and oncology. He has a B.S. degree in Applied Mathematics and his M.S. and Ph.D. degrees in Statistics from Texas A&M University.
Dr. Gilon has served as Anchiano’s VP of R&D since January 2013 and brings more than 15 years of research experience in the fields of molecular and developmental biology. In her work, Dr. Gilon implements interdisciplinary methodologies leading Anchiano’s pre-clinical activities to enable the successful initiation of the company’s clinical programs. Dr. Gilon also leads the research of new innovative therapeutic drug candidates. As part of her overall role, Dr. Gilon represents the company’s science in FDA meetings and global regulatory and advisory boards and brings a vast network of collaborative relationships from academic and clinical settings.
Dr. Gilon earned her PhD in the field of developmental biology from the Hebrew University of Jerusalem. She completed her post-doctoral studies leading projects investigating genetic and molecular mechanism of cancer under the mentorship of Prof. Avraham Hochberg, Anchiano’s Co-Founder and former Chief Scientist.
Mr. Daly has served as Anchiano’s Vice President of Clinical Operations since March 2018 and brings more than a decade of experience and an ample network of synergetic relationships to his role. Mr. Daly joined Anchiano from ARIAD Pharmaceuticals, where he most recently served as the Vice President of Clinical Operations. Sean led the clinical operations group at ARIAD for five years, building upon various operational roles held at ARIAD since 2004. In addition to his experience at ARIAD, he has held positions with Wyeth Research (formerly Genetics Institute) and Agouron Pharmaceuticals. Sean is a graduate of the University of California at San Diego where he received his B.S. in Biochemistry and Cell Biology.